Publications by authors named "Devi SenGupta"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

17,153

Total Likes

200

Extended Reach

1,080,353

Social Features

184
R
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.
Jason D Goldman, David C B Lye, David S Hui, Kristen M Marks, Raffaele Bruno, Rocio Montejano, Christoph D Spinner, Massimo Galli, Mi-Young Ahn, Ronald G Nahass

N Engl J Med· November 2020

Videos about Article: user user

2 25 182 1 7 14 1

View All Article and Social Media Activity
P
Predictors of virological outcomes after analytical interruption of antiretroviral therapy and HTI vaccination in early treated people with HIV-1._.
Lucia Bailón, Yovaninna Alarcón-Soto, José R Arribas, Adrian Curran, Anuska Llano, Devi SenGupta

Commun Med (Lond)· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effects of Cobicistat and Voriconazole on the Safety, Pharmacokinetics, and Pharmacodynamics of the TLR7 Agonist Vesatolimod in People with HIV.
Yanan Zheng, Mary Wire, Robert Were Omange, Christiaan R deVries, Liao Zhang, Devi SenGupta

Infect Dis Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trial.
Lucia Bailón, José Moltó, Adrian Curran, Julen Cadiñanos, Juan Carlos Lopez Bernaldo de Quirós, Devi SenGupta

Nat Commun· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential shaping of T cell responses elicited by heterologous ChAd68/self-amplifying mRNA SIV vaccine in macaques in combination with αCTLA4, αPD-1, or FLT3R agonist.
Amy R Rappaport, Elena Bekerman, Gregory R Boucher, Janette Sung, Brian Carr, Devi SenGupta

J Immunol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Viral Dynamics Predict Human Immunodeficiency Virus Posttreatment Control After Analytic Treatment Interruption.
Gesham Magombedze, Elena Vendrame, Devi SenGupta, Romas Geleziunas, Susan Little

J Infect Dis· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time to HIV viral rebound and frequency of post-treatment control after analytical interruption of antiretroviral therapy: an individual data-based meta-analysis of 24 prospective studies.
Jesper D Gunst, Jesal Gohil, Johanthan Z Li, Ronald J Bosch, Andrea White Catherine Seamon, Devi SenGupta

Nat Commun· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Pooled Analysis of Eight Clinical Studies Suggests a Link Between Influenza-Like Symptoms and Pharmacodynamics of the Toll-Like Receptor-7 Agonist Vesatolimod.
Sharon A Riddler, Constance A Benson, Cynthia Brinson, Steven G Deeks, Edwin DeJesus, Devi SenGupta

Infect Dis Ther· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIV rebound in HIV controllers is associated with a specific fecal microbiome profile.
Yanhui Cai, Ondrej Podlaha, Steven G Deeks, Cynthia Brinson, Moti N Ramgopal, Devi SenGupta

Eur J Immunol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating immune and plasma biomarkers of time to HIV rebound in HIV controllers treated with vesatolimod.
Mohamed Abdel-Mohsen, Steven Deeks, Leila Giron, Kai Ying Hong, Aaron Goldman, Devi SenGupta

Front Immunol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial.
Lucia Bailón, Anuska Llano, Samandhy Cedeño, Tuixent Escribà, Miriam Rosás-Umbert, Devi Sengupta

Nat Med· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus-1.
Sharon A Riddler, Michael Para, Constance A Benson, Anthony Mills, Moti Ramgopal, Devi SenGupta

Clin Infect Dis· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy.
Devi SenGupta, Cynthia Brinson, Edwin DeJesus, Anthony Mills, Peter Shalit

Sci Transl Med· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-stakeholder consensus on a target product profile for an HIV cure.
Sharon R Lewin, Timothy Attoye, Cathy Bansbach, Brian Doehle, Karine Dubé, Devi SenGupta

Lancet HIV· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.
Samir K Gupta, Frank A Post, José R Arribas, Joseph J Eron, David A Wohl, Devi SenGupta

AIDS· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks.
Rima K Acosta, Madeleine Willkom, Ross Martin, Silvia Chang, Xuelian Wei, Devi SenGupta

Antimicrob Agents Chemother· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial.
Joseph J Eron, Jean-Daniel Lelievre, Robert Kalayjian, Jihad Slim, Anson K Wurapa, Devi SenGupta

Lancet HIV· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Paul E Sax, Anton Pozniak, M Luisa Montes, Ellen Koenig, Edwin DeJesus, Devi SenGupta

Lancet· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-HERV-K (HML-2) capsid antibody responses in HIV elite controllers.
Miguel de Mulder, Devi SenGupta, Steven G Deeks, Jeffrey N Martin, Christopher D Pilcher

Retrovirology· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
p16INK4a Expression and Immunologic Aging in Chronic HIV Infection.
Susan Pereira Ribeiro, Jeffrey M Milush, Edecio Cunha-Neto, Esper G Kallas, Jorge Kalil, Devi SenGupta

PLoS One· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
Edwin DeJesus, Moti Ramgopal, Gordon Crofoot, Peter Ruane, Anthony LaMarca, Devi SenGupta

Lancet HIV· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
Chloe Orkin, Edwin DeJesus, Moti Ramgopal, Gordon Crofoot, Peter Ruane, Devi SenGupta

Lancet HIV· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relative mRNA Expression Levels of Restriction Factors and Antiviral Genes in Fetal and Adult Human Monocytes and Monocyte-Derived Macrophages.
Karen Trang, Rui André Raposo, Margaret M Lowe, Elisabeth R Krow-Lucal, Wes Yonemoto, Devi SenGupta

Viral Immunol· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: p16INK4a Expression and Immunologic Aging in Chronic HIV Infection.
Susan Pereira Ribeiro, Jeffrey M Milush, Edecio Cunha-Neto, Esper G Kallas, Jorge Kalil, Devi SenGupta

PLoS One· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis